Prix Gyre Therapeutics Inc (GYRE)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.